Santhera lays out options in bid for commercialization funds; Swiss biotech’s Covid work narrows
As Santhera waits for the FDA’s signal on its rolling NDA submission, the penny stock biotech is looking to secure more funding.
The Swiss penny …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
